Suchergebnisse - "van der Noll, Ruud"

PubPharm (7)

1

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

enthalten in: Nature cancer | 2022

von Tamborero, D. | Dienstmann, R. | Rachid, M. | +79

ErratumIn: Nat Cancer. 2022 May;3(5):649. - PMID 35449310

2

Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)

enthalten in: Investigational new drugs | 2020

von van der Noll, R. | Jager, A. | Ang, J. | +11

3

Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2)

enthalten in: Investigational new drugs | 2020

von van der Noll, R. | Jager, A. | Ang, J. | +12

4

A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors

enthalten in: The oncologist | 2017

von Leong, S. | Moss, R. | Bowles, D. | +9

5

First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2016

von Munster, P. | Aggarwal, R. | Hong, D. | +15

6

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer

enthalten in: British journal of cancer | 2015

von van der Noll, R. | Marchetti, S. | Steeghs, N. | +6

7

Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities

enthalten in: Cancer treatment reviews | 2013

von van der Noll, R. | Leijen, S. | Neuteboom, G. | +2

1
[1]